Oral Polio Vaccine
Identification
- Name
- Oral Polio Vaccine
- Accession Number
- DB15864
- Description
The oral polio vaccine (OPV) is a live attenuated vaccine containing a mixture of one or more strains of poliovirus serotypes. Strains of the virus are selected based on their reduced incidence of spreading to the central nervous system but still having the ability to mimic the immune response that occurs after infection with the wild poliovirus3. The vaccine is created by weakening the wildtype before being placed into the oral vaccine. After administration, OPV strains extensively multiply in the intestinal tract, becoming widely spread in the community to immunize a sizable proportion of those unvaccinated in the population1. With administration, this vaccine prevents cases of paralytic poliomyelitis.
The polio vaccine can be either administered in the inactivated form or the oral form, although both series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are completed2.
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- OPV
- External IDs
- Oral Polio Vaccine
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
The polio vaccine allows for the encounter of the polio virus by the immune system to be less threatening while still allowing for the body to mount a humoral response for protection against any future exposure of the virus2. For the OPV specifically, upon administration, the vaccine elicits a local immune response in the intestinal mucous membranes, a location at which the poliovirus multiplies3. Antibodies produced locally then will inhibit multiplication of following infections of the wildtype poliovirus3.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Sabin AB: Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 1985 Mar;151(3):420-36. doi: 10.1093/infdis/151.3.420. [PubMed:2982959]
- O'Grady M, Bruner PJ: Polio Vaccine . [PubMed:30252295]
- WHO Oral Polio Vaccine [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on September 18, 2020 22:04 / Updated on February 13, 2021 10:53